Researchers integrating transcriptomic and clinical profiling identified a monocyte-linked peripheral complement remodeling ...

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease ...

Annexon (NASDAQ:ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of 2026 ...

Researchers find that a lipid damage signal both activates and limits the complement system during cell death, helping ...

Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart ...

Ali Habib, MD, a neuromuscular specialist at UCI Health, breaks down the phase 3 NIMBLE trial's patient population, four ...

Target discovery and drug development often require different expertise. Through an immunology programme based on co-creation ...

Annexon's stock hinges on the Q4 2026 readout of its Phase 3 ARCHER II trial's month-15 primary endpoint in geographic ...

Cold AgglutininsLab Interpretation A high cold agglutinin titer means antibodies remain detectable after substantial dilution ...

The team utilized a multistage in silico workflow to screen a library of nearly 30,000 compounds, ultimately prioritizing ...

Pegtarazimod blocks the C1 complex and the initiators of both the classical and lectin pathways of inflammation. The peptide ...

Omeros had submitted substantial patient-level data to CHMP in August as part of its grounds for re-examination. CHMP did not provide patient-level data to the AHEG. Narsoplimab was approved under the ...